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Abstract: Antony J Workman, Kathleen A Kane, Julie A Russell, John Norrie, Andrew C Rankin. 
Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of 
pharmacological remodelling. Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment 
reduces the incidence of reversion to AF in patients, possibly via an adaptive myocardial response. However, 
the underlying electrophysiological mechanisms are presently unclear. We aimed to investigate 
electrophysiological changes in human atrial cells associated with chronic treatment with β-blockers and 
other cardiovascular-acting drugs. Methods: Myocytes were isolated enzymatically from the right atrial 
appendage of 40 consenting patients who were in sinus rhythm. The cellular action potential duration (APD), 
effective refractory period (ERP), L-type Ca
2+
 current (ICaL), transient (ITO) and sustained (IKSUS) outward K
+
 
currents, and input resistance (Ri) were recorded using the whole cell patch clamp. Drug treatments and 
clinical characteristics were compared with electrophysiological measurements using simple and multiple 
regression analyses. P<0.05 was taken as statistically significant. Results: In atrial cells from patients treated 
chronically with β-blockers, the APD90 and ERP (75 beats/min stimulation) were significantly longer, at 
213±11 and 233±11 ms, respectively (n=15 patients), than in cells from non-β-blocked patients, at 176±12 
and 184±12 ms (n=11). These cells also displayed a significantly reduced action potential phase 1 velocity 
(22±3 vs 34±3 V/s). Chronic β-blockade was also associated with a significant reduction in the heart rate 
(58±3 vs 69±5 beats/min) and in the density of ITO (8.7±1.3 vs 13.7±2.1 pA/pF), an increase in the Ri 
(214±24 vs 132±14 MΩ), but no significant change in ICaL or IKSUS. The ITO blocker 4-aminopyridine largely 
mimicked the changes in phase 1 and ERP associated with chronic β-blockade, in cells from non-β-blocked 
patients. Chronic treatment of patients with calcium channel blockers or angiotensin converting enzyme 
inhibitors (n=11-13 patients) was not associated with any significant changes in atrial cell electrophysiology. 
Conclusion: The observed atrial cellular electrophysiological changes associated with chronic β-blockade 
are consistent with a long term adaptive response, a type of “pharmacological remodelling”, and provide 
mechanistic evidence supportive of the anti-arrhythmic actions of β-blockade. 
 
Keywords: Discipline: Experimental; Objective: Heart; Level: Cellular; Field: Electrophysiology, 
Pathophysiology, Pharmacology. Additional keywords: Antiarrhythmic agents; Arrhythmia (mechanisms); 
Remodeling; Myocytes; Ion channels. 
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Introduction 
 Atrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance. It is associated with a 
substantial decrease in the quality and expectancy of life, and is becoming more prevalent [1]. Beta-
adrenoceptor antagonists (β-blockers) have a well established efficacy for controlling the ventricular rate 
during AF, by slowing atrioventricular conduction. β-blockade is also recognised to reduce the recurrence of 
adrenergically-mediated AF, for example after cardiothoracic surgery [2]. However, evidence is 
accumulating that β-blockade may also exert anti-arrhythmic actions in other groups of patients with AF. 
Metoprolol was more effective than placebo [3], and bisoprolol was as effective as sotalol [4], in preventing 
relapse into AF after cardioversion. Additionally, atenolol reduced the incidence and duration of paroxysmal 
AF [5]. 
 The mechanisms of these β-blocker effects are presently unclear, but may involve a long term adaptive 
change in myocardial electrophysiology. Animal studies have indicated that chronic β-blockade prolonged 
the action potential duration (APD) in atria and ventricles [6]. However, the effects of chronic β-blockade on 
human myocardial repolarisation are presently unclear, with conflicting reports in the ventricle (lengthening 
[7] and shortening [8]) and no available data, to our knowledge, in the atrium. 
 AF is maintained by intra-atrial reentry, facilitated by a shortened atrial effective refractory period 
(ERP). Atrial electrophysiological remodelling due to AF contributes to stabilisation of the arrhythmia, and 
is associated with shortening of the APD and ERP, as confirmed recently in our laboratory in human atrial 
myocytes [9]. It is conceivable, therefore, that the anti-fibrillatory effects of β-blockers might involve, 
through an adaptive response to their chronic use, a prolongation of the atrial cell APD and ERP. We wished 
to test this hypothesis, examine potential ionic mechanisms involved, and assess, for comparison, 
electrophysiological changes associated with chronic use of other drugs acting on the cardiovascular system. 
 The objective, therefore, was to investigate changes in human atrial cell action potentials, ERP and ion 
currents associated with chronic use of β-blockers and other cardiovascular-acting drugs. 
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Methods 
Cell isolation 
 Right atrial appendage tissue was obtained from 40 patients undergoing corrective cardiac surgery 
(Table 1). Procedures approved by the institutional research ethics committee were followed, and each 
patient's informed consent was obtained. The investigation conforms with the principles outlined in the 
Declaration of Helsinki [10]. Atrial cells were isolated enzymatically with protease (Type XXIV, Sigma, 
4U/ml) and collagenase (Type 1, Worthington, 400 U/ml) using the method described previously [9].  
 
Electrical recording 
Action potentials and ion currents were recorded using the whole cell patch clamp technique, with an 
Axopatch-1D amplifier (Axon Instruments). Cells were superfused at 37
o
C with a physiological salt solution 
containing (mM): NaCl (130.0), KCl (4.0), CaCl2 (2.0), MgCl2 (1.0), glucose (10.0) and HEPES (10.0). The 
pipette solution contained (mM): K-aspartate (110.0), KCl (20.0), MgCl2 (1.0), EGTA (0.15), Na2ATP (4.0), 
Na2GTP (0.4) and HEPES (5.0). Series resistance and capacitative transients were compensated 
electronically prior to recording. Action potentials were stimulated using 5 ms duration current pulses of 1.2x 
threshold strength, after current clamping the resting potential to -75 mV and keeping the holding current 
constant thereafter. The ERP was measured using a standard S1-S2 stimulation protocol, with an 8-pulse 
conditioning train (75 beats/min), and S1 and S2 pulses of equal magnitude. The ERP was defined as the 
longest S1-S2 interval failing to elicit an S2 action potential of amplitude >80% of the preceding S1 action 
potential. The APD was calculated as the interval between the action potential upstroke and repolarisation to 
the level of both 50 and 90% (APD50 and APD90, respectively). The voltage clamp was used to record the 
cells’ input resistance (Ri), the L-type Ca
2+
 current (ICaL), the transient outward K
+
 current (ITO) and the 
sustained outward K
+
 current (IKSUS). Ri was determined using a linear voltage ramp (increasing from -120 
mV to +50 mV in 7 s) from the slope of the ohmic portion of the resulting current-voltage relationship, 
usually between -120 mV and -100 mV. ICaL was stimulated from a holding potential of -40 mV, with 100 ms 
pulses (0.33 Hz), increasing from -30 mV to +50 mV in 10 mV steps. ICaL was measured at each voltage step 
as the peak inward deflection minus the current at the end of the pulse. ITO and IKSUS were stimulated from a 
holding potential of -60 mV, with 100 ms pulses (0.33 Hz), increasing from -50 mV to +60 mV in 10 mV 
steps. IKSUS was measured as the steady-state (end-pulse) current, and ITO as the peak positive deflection 
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minus the end-pulse current at each voltage step. The same electrode filling solution was used for recording 
action potentials and ion currents, permitting their comparison under constant ionic conditions, and often in 
the same cell. Contamination of ICaL and ITO by K
+
 currents was minimised as far as possible, by the 
subtraction of the steady-state currents. Each current’s density was calculated as the peak amplitude (ie: at 
+10 mV for ICaL, +60 mV for ITO and +60 mV for IKSUS) divided by the cell’s capacity, prior to the statistical 
analyses and graphing of mean data. Action potentials and ion currents were stimulated, recorded and 
measured using “WinWCP” software, donated by J Dempster, Strathclyde University. 
 
Data analysis and statistics 
 Details of each patient’s clinical characteristics and drug treatments were obtained from the case notes. 
The cardiac rhythm and heart rate were assessed from the pre-operative electrocardiogram. Only those 
patients in sinus rhythm at the time of surgery were included. Patient and associated cellular 
electrophysiological data were stored in a database (Access, Microsoft) for subsequent analysis. Univariate 
electrophysiological measurements were compared between pairs of various subgroups of patients using 2-
sided, 2-sample unpaired Student's t tests. Univariate data are expressed as cell means±standard error (SE). 
Multiple linear regression [11] was then used to further investigate associations between patients’ atrial 
electrophysiology and drug treatments or clinical characteristics. This provided an estimate of the difference 
in each electrophysiological measurement between the levels of the factor of interest, according to 8 
variables considered to be of particular importance. These were the patients’ drug treatments (β-blockers, 
calcium channel blockers [CCBs] and angiotensin converting enzyme [ACE] inhibitors), age (for a 5 year 
increase), sex, heart rate (for a 5 beats/min increase), and the presence or absence of coronary artery bypass 
graft (CABG) surgery or previous myocardial infarction. Two multiple regressions were fitted: firstly, by 
taking into account all covariables, and secondly (when comparing patients taking a drug with those not), by 
taking as covariables only those drugs additional to the one under consideration. All analyses were 
performed using “SAS 8.2 for Windows NT” software. No adjustment was made for multiple comparisons. 
P<0.05 was regarded as statistically significant.  
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Results 
Patients’ drug treatments 
 The patients’ characteristics are shown in Table 1. Drugs were administered chronically, with each 
patient receiving their routine cardiac drugs on the day of surgery. All patients undergoing β-blockade were 
treated with cardiac selective β1-adrenoceptor antagonists, with 88% on atenolol, 8% on metoprolol and 4% 
on bisoprolol. No patients were administered sotalol (which has additional class III activity). Of the patients 
treated with CCBs, 33% were receiving diltiazem, a predominantly cardiac-acting drug. The remaining 67% 
were taking drugs with mixed vascular and cardiac actions, but with vascular activity predominating, 
including amlodipine (44%), nifedipine (17%) and nicardipine (6%). Twelve patients were taking both β-
blockers and CCBs. The ACE inhibitors administered included lisinopril (50%), captopril (21%), ramipril 
(21%) and enalapril (7%). Of the 14 patients on ACE inhibitors, 9 were on β-blockers, and 6 on CCBs. All 
cardio-active drugs had been administered for a minimum duration of 3 months. 
 
Atrial cellular electrophysiological changes associated with chronic β-blockade 
 Figure 1A shows original action potential traces and ERP measurements, from single atrial cells 
representative of patients not treated (top trace) and treated (bottom trace) with β-blockers. Chronic β-
blockade was associated with a lengthening of both the ERP and late repolarisation. Univariate analysis 
(simple regression) indicated that the mean APD90 and ERP were markedly and significantly longer in atrial 
cells from the patients receiving β-blockers, at 213±11 ms (n=21 cells, 15 patients) and 233±11 ms (n=16 
cells, 11 patients), respectively, than in the non-treated patients, at 176±12 ms (n=20 cells, 11 patients) and 
184±12 ms (n=17 cells, 10 patients), respectively (Figure 1B). The univariate means within each patient 
group, and the probability values of differences between groups, were similar whether analysed at cell or 
subject (patient) level. The changes in APD and ERP associated with chronic β-blockade were independent 
of cell capacity or holding current, each of which were similar in β-blocker-treated and non-treated patients, 
at 74±4 pF (n=36 cells, 21 patients) vs 81±3 pF (n=28 cells, 15 patients, P=0.22), and 57±7 pA (n=30 cells, 
18 patients) vs 60±7 pA (n=16 cells, 9 patients, P=0.70), respectively. The mean action potential overshoot, 
amplitude and maximum upstroke velocity (Vmax) were not significantly different between the cells from 
patients receiving β-blockers (48±2 mV, 126±3 mV and 149±16 V/s; n=21 cells, 15 patients, respectively) 
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and those who were not (53±2 mV, 130±2 mV and 176±15 V/s; n=20 cells, 11 patients, respectively). The 
heart rate was significantly slower in the patients undergoing β-blockade (58±3 vs 69±5 beats/min; P=0.02, 
n=25 and 15, respectively). Multiple regression analysis was used to further investigate associations between 
patients’ characteristics and electrophysiological changes. Table 2 provides an example of this analysis with 
respect to the atrial cell ERP. With ACE inhibitors and CCBs taken as covariables (“Drugs”), the direction, 
magnitude and probability value of the estimated difference in ERP between β-blocker-treated and non-
treated patients were similar to that found without adjusting for these covariables. When all covariates were 
considered (“All”), the direction and approximate magnitude of the difference were again maintained, 
although the difference was no longer significant. A similar analysis of the APD90 also provided data 
supportive of the univariate association between β-blockade and APD-lengthening, with an estimated 
prolongation of 40 ms with drugs as covariables. Simple and multiple regression analysis revealed no 
significant associations between atrial cell ERP and the patient’s age, heart rate, or presence of previous 
myocardial infarction (Table 2). However, simple (but not multiple) regression indicated that both CABG 
surgery and male sex were associated with prolongation of the ERP. 
 The amplitude and density of ITO were markedly smaller in atrial cells from the patients treated with β-
blockers than in those from untreated patients, as shown by the representative traces of Figure 2A, and the 
univariate analysis in Figure 2D. Additionally, the Ri was higher in the atrial cells from patients who 
underwent β-blockade than in untreated patients. This is illustrated in Figure 2C (lower trace), by the 
relatively shallow slope of the ohmic portion of the current-voltage relationship, and confirmed by univariate 
analysis (Figure 2D). The tangent to the ohmic portion intersected zero current at -81±3 mV (n=15 cells), 
compared with the predicted K
+
 equilibrium potential of -93 mV. This suggested that Ri was contributed to 
by the inward rectifier K
+
 current (IK1). The density of atrial IKSUS was not significantly different between 
patients who were, and who were not, treated with β-blockers, at 8.81±1.74 pA/pF (n=10 cells, 7 patients) 
and 7.37±1.14 pA/pF (n=8 cells, 4 patients, respectively; P=0.77), as represented in Figure 2A. The density 
of ICaL also was not significantly different between treated and untreated patients, at -6.76±1.14 pA/pF (n=17 
cells, 8 patients) and -4.77±0.99 pA/pF (n=6 cells, 4 patients, respectively (P=0.34), as represented in Figure 
2B. These data for ITO, Ri, IKSUS and ICaL were supported by multiple regression: with the “Drugs” model, the 
estimated magnitude of the reduction in ITO was 6.9 pA/pF (P=0.03). In this analysis, the magnitude (but not 
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the probability value) of the increase in Ri was also maintained. The absence of significant change in ICaL and 
IKSUS was also confirmed, whether the analysis incorporated all of the covariables, or the drugs alone. Since a 
reduction in atrial ITO has also been associated with congestive heart failure [12], a sub-analysis of 
electrophysiological data was performed in patients with and without significant (moderate or severe) left 
ventricular dysfunction (LVD). Eleven of the 25 β-blocker-treated patients (44%) had significant LVD, and 4 
of the 15 non-β-blocker-treated patients (27%) had significant LVD. There was no significant difference in 
the proportion of patients with significant LVD between the two patient sub-groups (P=0.28). Within both of 
these sub-groups, there was no significant difference between patients with and without LVD, in the atrial 
cell ERP, APD90, ITO or Ri. 
 The potential contribution of the observed reduction in atrial ITO to associated changes in repolarisation 
and refractoriness was evaluated. Chronic β-blockade, in addition to prolonging the ERP (Figure 1), was 
associated with a significant slowing of the action potential maximum downstroke velocity, phase 1 Vmax 
(Figure 3A). The ITO blocker 4-aminopyridine (4-AP) produced a similar reduction in phase 1 Vmax in cells 
from non-β-blocker-treated patients (Figure 3B), which was also accompanied by a significant prolongation 
in the ERP (Figure 3C). 
 
Lack of electrophysiological changes associated with calcium channel blockade or ACE inhibition 
 Chronic calcium channel blockade or ACE inhibition was not associated with any significant changes in 
the APD or ERP, as indicated by univariate mean data, shown in Figure 4. The action potential overshoot, 
amplitude and Vmax were 49±2 mV, 128±2 mV and 160±17 V/s, respectively, in atrial cells from patients not 
treated with CCBs, and 51±2 mV, 128±3 mV and 164±15 V/s, respectively, in cells from patients not treated 
with ACE inhibitors. Chronic treatment with either drug was not significantly associated with a change in 
any of these values. A comparison of data from patients receiving CCBs acting predominantly on the 
myocardium with those exerting mixed actions but mainly affecting the vasculature, indicated no significant 
differences in atrial cell electrophysiology between the drug sub-types. For example, the ERP in patients 
receiving cardiac- and vascular-acting drugs was 223±13 and 201±26 ms, respectively, not significantly 
different from each other or from the combined mean (214±13 ms). There were also no significant 
differences in the magnitudes of ICaL, ITO, IKSUS, or the Ri between patients treated and not treated with either 
CCBs or ACE inhibitors. Multiple regression analysis supported the lack of association between action 
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potential configuration, duration, the ERP, ion currents, and treatment with either CCBs or ACE inhibitors. 
Table 2 provides an example of this, indicating a lack of statistical significance of any estimated difference 
in the ERP between non-treated and treated patients, at either level of analysis, ie: with drugs alone, or with 
consideration of all covariates.
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Discussion 
 We report the novel finding that chronic β-blockade was associated with prolongation of action 
potentials and the ERP in human atrial cells. These changes represent an adaptive response, a type of 
“pharmacological remodelling”, whereby chronic blockade of the β-adrenoceptors resulted in alterations of 
ion current density, recorded independently of receptor occupancy, ie: in the absence of drugs. This response 
may contribute to the anti-fibrillatory actions of β-blockade by prolonging refractoriness, and thus 
lengthening the minimum path length required for reentry. Moreover, during β-blocker therapy, such actions 
may be enhanced by the presence of the drug itself and would also persist in patients who miss a dose, which 
may offset the potentially pro-arrhythmic effects of increased atrial sensitivity to catecholamines and 5-HT 
[13-15]. 
 Our results are the first, to our knowledge, to be obtained from human atrium, and are consistent with 
previous studies in animals [6,16]. Thus, chronic metoprolol treatment in rabbits lengthened the atrial APD, 
as well as the ventricular APD and ERP, and the QTc interval [6], and the atrial effects were similar in 
magnitude to those reported here. In humans, only effects on the ventricle have been studied, and chronic β-
blockade prolonged both QT interval and monophasic action potentials [7,17] especially during exercise 
[18]. However, an absence of change [19,20] or even a shortening [8], in QT interval or ERP have also been 
reported. Differences between human atrial and ventricular responses may be expected, in view of, for 
example, the presence of a sustained outward current in human atrium but not ventricle, and the relatively 
slow recovery kinetics of atrial ITO [21]. Additionally, pharmacological remodelling by β-blockade in the 
rabbit was more rapid in the atrium than in the ventricle [6]. 
 The present study also addressed ionic changes underlying the effects of chronic β-blockade in 
human myocardium. We demonstrated a reduction in atrial ITO associated with chronic β-blockade, and 
provided evidence to suggest that this may be a contributory ionic mechanism for the lengthening of the 
action potential and ERP. Thus, the velocity of phase 1, which is dependent on the magnitude of both ITO and 
ICaL, was reduced by chronic β-blockade, in the absence of a change in ICaL. Furthermore, β-blocker-induced 
changes in both phase 1 and ERP were largely mimicked, in cells from non-β-blocker-treated patients, by the 
ITO blocker, 4-AP. However, it is recognised that 4-AP, whilst the most specific ITO blocker currently 
available, also blocks the ultra-rapid delayed rectifier K
+
 current, IKur, at concentrations well below those 
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required to block ITO, and, therefore, that the effects of 4-AP on both the APD and ERP should be interpreted 
with caution. A further potential limitation is that a reduced density of atrial ITO has been demonstrated in 
dogs with congestive heart failure, associated with an increase in cell capacity, but with no change in APD at 
physiological rate [12]. In the present study, however, the effects of chronic β-blockade to reduce ITO density 
were independent of cell capacity, which was similar in treated and untreated groups. Moreover, the atrial 
cell APD, ERP, ITO density and Ri were all similar in the patients with and without left ventricular 
dysfunction. Chronic β-blockade was associated with an increase in atrial Ri, which may be expected to have 
been due, at least in part, to a decrease in IK1. However, it is acknowledged that IK1 was not measured 
directly, and that a change in IK1 might have occurred within the physiological voltage range, rather than at 
the potentials at which changes in Ri were observed. Nevertheless, our data raise the possibility that IK1 may 
decrease as a result of chronic β-blockade, and as such, a contribution to the associated lengthening in the 
APD and ERP cannot be excluded.  
 The mechanisms of these electrophysiological changes associated with chronic β-blockade are presently 
unclear. A chronically slowed heart rate by β-blockade might lengthen the atrial APD and ERP recorded at 
constant stimulation rate, analogous to their shortening resulting from chronic fast atrial rate [9]. However, 
the multiple regression analysis indicated that the observed prolongation of APD and ERP was independent 
of heart rate. An alternative mechanism is a direct regulation of expression of ion channels by chronic β-
receptor modulation. Chronic β-blockade alone has not been studied, but chronic β-stimulation has been 
shown to alter ion channels, via mechanisms including cAMP-regulated modification of transcription 
[22,23]. In guinea pig cultured ventricular myocytes, exposure to isoproterenol for 48 hours reduced the 
density of IK1, ICaL, and the delayed rectifier current IKs, which was reversed by co-incubation with 
propranolol [22]. Additionally, chronic β-stimulation increased the density of ITO in canine cultured 
ventricular myocytes [24], and an increase in both ITO and IK1 occurred during sympathetic innervation of 
newborn rat hearts [25]. If one speculated that chronic β-blockade might produce the opposite effects, then a 
reduced ITO and IK1, as reported here, would be predicted by some [24,25], but not all [22], studies. 
 Chronic calcium channel blockade or ACE inhibition were not associated with adaptive changes in atrial 
ion currents, action potentials or the ERP. Human atrial ICaL was increased by acute ACE inhibition [26], but 
no studies could be found with chronic ACE inhibition. In a single report of effects of chronic CCB 
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treatment on human atrial electrophysiology [26], a reduction in both the APD50 and ICaL was observed. 
Whilst the ERP was unchanged, consistent with our study, it is unclear why our results differ with respect to 
APD50 and ICaL. Animal studies of chronic calcium channel blockade have shown an absence of change in 
several myocardial electrophysiological and related measurements, including reports of no change [27], and 
even an increase [28] in ICaL. Consistent with the presently observed absence of associated atrial 
electrophysiological changes, neither chronic calcium channel blockade nor ACE inhibition has a proven 
efficacy in the treatment of AF [29]. 
 Pharmacological intervention is the mainstay of current treatment for AF. However, the use of anti-
arrhythmic agents with established efficacy for treating AF, ie: from classes 1C and III, may be precluded by 
the presence of associated heart disease and risk of serious side effects [29]. The role of β-blockers in the 
treatment of patients with AF is becoming increasingly recognised [3-5]. The presently observed atrial 
cellular adaptive electrophysiological responses to chronic β-blockade provide mechanistic evidence 
supportive of the anti-arrhythmic actions of β-blockade. 
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Table and Figure legends 
 
Table 1. Patients’ characteristics. 
Values are numbers of patients (n and % of total, respectively) with selected clinical characteristics, except 
for age (mean±SE). CCB=calcium channel blocker, CABG=coronary artery bypass graft surgery, 
AVR=aortic valve replacement, ASD=atrial septal defect, VSD=ventricular septal defect, LV=left 
ventricular, MI=myocardial infarction. All patients were in sinus rhythm at the time of surgery. 
 
Table 2. Multiple regression analysis of the atrial cell refractory period. 
ERP=effective refractory period, ACEI=ACE inhibitors, BB=β-blockers, HR=heart rate. The model is either 
“Alone” (univariate), “Drugs” (adjusting for all drugs) or “All” (adjusting for all covariates). ERP 
estimate=estimated difference in mean ERP between highest (eg: drug-treatment) and lowest (eg: non-drug-
treatment) level of variable, or male minus female. Values are subject (patient) means±standard error (SE); 
*=P<0.05. 
 
Figure 1. 
Atrial cell action potential and refractory period changes associated with chronic β-blocker treatment. 
A, Superimposed action potentials in response to the 7th and 8th of a train of 8 conditioning, S1, pulses (basic 
rate: 75 beats/min) followed by responses to an increasingly premature test, S2, pulse ( in an atrial cell from a 
patient not treated () and treated () with a β-blocker. The effective refractory period (ERP), indicated in 
each panel by a solid bar, was calculated as the longest S1-S2 interval failing to elicit an S2 response of 
amplitude >80% of the preceding S1 action potential. In each case, the S2 response thus used to measure this 
interval is labelled (). B, Mean (±SE) atrial cell action potential duration measured at 50 and 90% 
repolarisation (APD50 and APD90, respectively) and ERP in cells from patients not undergoing (: n=17-20 
cells, 10-11 patients) or undergoing (!: n=16-21 cells, 11-15 patients) chronic β-blockade. *=P<0.05 
between patient groups. 
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Figure 2. 
Ion current changes associated with chronic β-blockade. 
A, Transient outward K
+
 currents, ITO (positive deflections), and sustained outward K
+
 currents, IKSUS (end- 
pulse currents); B, L-type Ca
2+
 currents, ICaL (negative deflections); C, Pseudo steady-state current-voltage 
relationships, in cells from patients not treated () and treated () with a β-blocker. D, Mean (±SE) ITO peak 
density and cell input resistance, Ri, in cells from non-β-blocker-treated patients (: n=8 cells, 4 patients for 
ITO and 28 cells, 13 patients for Ri, respectively) or treated patients (!: n=10 cells, 7 patients for ITO and 36 
cells, 18 patients for Ri, respectively). *=P<0.05 between patient groups. 
 
Figure 3. 
Contribution of transient outward current to chronic β-blocker effects on action potentials and refractoriness. 
A, Atrial action potential phase 1 maximum downstroke velocity (Phase 1 Vmax) in cells from patients not 
treated (: n=17 cells, 10 patients) or treated (!: n=16 cells, 11 patients) with β-blockers. B, Phase 1 Vmax, 
and C, Effective refractory period (ERP) in cells from non-β-blocker-treated patients, in the absence (open 
bars) and presence (striped bars) of 2 mM 4-aminopyridine (90 s superfusion; n=4 cells, 2 patients). All 
values in A-C are means (±SE), with asterisks denoting P<0.05 between groups. 
 
Figure 4. 
Lack of change in APD or ERP associated with chronic calcium channel blockade or ACE inhibition. 
Mean (±SE) atrial cell action potential duration measured at 50 and 90% repolarisation (APD50 and APD90, 
respectively) and effective refractory period (ERP) in cells from patients not treated (open bars, n=17-21 
cells, 12-13 patients) or treated (hatched bars, n=18-20 cells, 11-13 patients) with A, Calcium channel 
blockers, or B, ACE inhibitors. NS=P>0.05. 
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Table 1 
 
 
  n % 
Patient details 
 
Male/female 
Age (years) 
32/8 
58±2 
80/20 
- 
Drug treatments Lipid lowering 27 68 
 β-blocker 25 63 
 Nitrate 25 63 
 CCB 18 45 
 ACE inhibitor 14 35 
 Diuretic 9 23 
 Digoxin 2 5 
Operation type CABG 30 75 
 AVR 4 10 
 AVR+CABG 3 7 
 ASD repair 2 5 
 VSD repair 1 3 
LV function Normal 19 47 
 Mild/moderate 17 43 
 Severe dysfunction 4 10 
Disease Angina 33 82 
 Hyperlipidaemia 26 65 
 Hypertension 18 45 
 Previous MI 16 40 
 Diabetes 4 10 
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Table 2 
 
 
Variable Multiple 
regression 
model 
ERP 
estimate 
(ms) 
ERP 
SEM 
P 
ACEI Alone +13.7 22.1 0.54 
 Drugs +11.3 18.9 0.56 
 All -9.3 18.1 0.62 
BB Alone +55.8 18.1 0.01* 
 Drugs +55.8 18.7 0.01* 
 All +38.5 21.4 0.09 
CCB Alone +10.5 22.0 0.64 
 Drugs +13.7 18.7 0.47 
 All +15.1 17.2 0.40 
Age Alone 0.0 4.6 0.99 
 All -4.8 3.9 0.24 
Sex Alone +86.8 19.9 0.01* 
 All +51.9 45.3 0.27 
CABG Alone +73.2 19.8 0.01* 
 All +50.1 44.4 0.28 
MI Alone +13.3 22.6 0.56 
 All -20.1 18.8 0.30 
HR Alone -4.4 3.1 0.16 
 All -0.8 2.6 0.76 
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Figure 1
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Figure 2 
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Figure 3
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Figure 4 
 
 
 
 
0
100
200
Duration
(ms)
APD50 APD90 ERP
NS
NS
NS
0
100
200
Duration
(ms)
APD50 APD90 ERP
NS
NS
NS
A 
B 
